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palmitate-induced in HepG2 hepatocytes
as a cellular steatosis model
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Abstract
Background: Oligonol is a low molecular weight form of polyphenol polymers derived from lychee fruits. Several studies
suggest that Oligonol has an anti-obesity effect. Since obesity is tightly associated with insulin resistance, we investigated
a possible remission effect of Oligonol on lipid accumulation and insulin resistance in human hepatic HepG2 cells.
Methods: HepG2 cells were treated with palmitate for 24 h to induce cellular hepatic steatosis and insulin resistance.
The cells were then treated with Oligonol at subtoxic concentrations and examined for lipid metabolism, cytokine
production, and insulin signaling using quantitative RT-PCR and western blot analysis.
Results: Oligonol treatment reversed the palmitate-induced intracellular lipid accumulation, down regulated the
expression of lipogenic genes, and up-regulated genes for fatty acid degradation. Oligonol restored insulin sensitivity,
as was determined by the phosphorylation states of IRS-1. Oligonol also inhibited STAT3-SOCS3 signaling and increased
AMPK phosphorylation in HepG2 cells.
Conclusion: Oligonol treatment improved palmitate-induced cellular steatosis and insulin resistance in HepG2 cells
with concomitant reduction of inflammatory cytokines and decrease in STAT3-SOCS3 and AMPK-mTOR pathways.
Oligonol may have beneficial effects in lipid metabolism and insulin resistance in the liver.
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Background
The mammalian liver controls the metabolic homeostasis
for carbohydrates, lipids, and proteins. Functional failure
of the organ is detrimental to an organism. Non-alcoholic
fatty liver disease (NAFLD) is a broadly defined term for
fatty liver-related diseases [1, 2]. An early form of NAFLD
is hepatic steatosis, characterized by the deposition of
triglycerides in the liver as lipid droplets. Hepatic steatosis
makes patients prone to more serious forms of NAFLD,
such as non-alcoholic steatohepatitis (NASH) and
liver cancer. Currently, there are not many therapeutic
options for these diseases as the pathologies are not well
understood [1].
The “two-hit hypothesis” has been proposed to
understand the pathogenesis of NAFLD [3]. The “first
hit” involves the deposition of triglycerides (TGs) and
free fatty acids in hepatocytes, leading to the development
of simple steatosis and insulin resistance, and the “second
hit” involves hepatic injury, inflammation, and fibrosis,
which are closely associated with oxidative stress in the
liver [4, 5]. Lipid peroxidation, production of inflammatory
cytokines, and mitochondrial dysfunction are the attributes
of inflammatory stress [6]. To study hepatic steatosis in
vitro, a cellular hepatic model was previously established
by treating human HepG2 hepatocarcinoma cells with free
fatty acids (FFAs) [7]. Upon treatment with palmitate (PA),
a saturated fatty acid, these cells show excess accumulation
of cytosolic lipids [7], activation of lipogenic genes [8],
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and development of insulin resistance [9, 10], which
are the cellular aspects of hepatic steatosis.
Oligonol is a low molecular weight oligomer of long-
chain polyphenols, typically proanthocyanidin found in
various fruits, including lychees [11, 12]. Polyphenols
derived from fruits and vegetables are known to function as
anti-inflammatory and chemopreventive agents on various
human diseases [13–15]. Despite its relatively recent
introduction, Oligonol has been shown to display potential
therapeutic effects on cancer, neurological, or metabolic
disorders [11, 16]. Particularly, a randomized clinical trial
showed that Oligonol reduces abdominal circumference
and visceral fat, results in weight loss, and improves insulin
resistance in healthy obese individuals [17]. Therefore, we
hypothesized that Oligonol induced anti-inflammatory
mechanisms and prevented the development of hepatic
steatosis and liver damage.
The present study evaluated the effects of Oligonol in
reducing hepatic steatosis in PA-treated HepG2 cells.
This study showed that Oligonol suppressed de novo fatty
acid synthesis and inflammatory cytokine production,
which are associated with the inhibition of STAT3–SOCS3
and AMPK-mTOR.
Methods
Cell culture and Oligonol treatment
Human HepG2 cell line (a gift from Dr. E.-J. Lee at Yonsei
University College of Medicine, Korea) was maintained in
Hyclone Dulbecco’s Modified Eagle’s Medium (DMEM;
Thermo Scientific, Rockford, IL, USA) containing 10 %
fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL
streptomycin. Cells were cultured in 5 % CO2 at 37 °C.
Oligonol (KCF Korea Co., Seoul, Korea) was dissolved in
double-distilled H2O (ddH2O), diluted in DMEM, and
used to treat HepG2 cells. The final quantity of solvent
did not exceed 0.1 % of culture media for all experiments.
MTT assay
HepG2 cells were grown in 96-well plate with different
concentrations of Oligonol for 24 or 48 h. Cell viability
was determined by colorimetry using the 3-(-4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) (USB corporation, Cleveland, OH, USA; Sigma-
Aldrich, Oakville, Canada). Insoluble formazan crystals
were dissolved in DMSO and the absorbance was measured
at 490 nm in a microplate reader (Molecular Devices,
Mountain View, CA, USA).
Preparation and treatment of sodium palmitate in
HepG2 cells
After reaching 80 % confluence, the cells were cultured
with fetal bovine serum-free medium containing 5 % bovine
serum albumin (BSA) overnight in a 6-well plate. Sodium
palmitate (Sigma-Aldrich) was conjugated to fatty acid free-
BSA (Sigma-Aldrich). Briefly, 69.6 mg sodium palmitate
was dissolved in 1 ml sterile water by alternating heating
and vortexing at 70 °C to obtain 250 mM stock solution.
Immediately after the dissolution of PA, the stock solution
was added to serum-free DMEM containing 5 % fatty acid-
free BSA to obtain 250 μM PA solution. This solution was
used to treat the cells [18]. Cells were treated with 200 μL
of 250 μM PA or with different concentrations of Oligonol
(1, 5, or 10 μg/ml) for 24 h. Cells cultured in a medium
containing 5 % BSA were used as a control.
Oil Red O staining
HepG2 cells grown in 6-well plates were collected,
washed with phosphate buffered saline, and fixed with
4 % paraformaldehyde for 1 h. Cells were rinsed with
ddH2O, dipped in 60 % isopropanol for a few seconds,
stained with Oil Red O (Sigma Chemical, St. Louis, MO,
USA) for 10 min, and rinsed with ddH2O few times to
remove the excess stain. Cell nuclei were stained with
hematoxylin for a few seconds and washed with ddH2O.
Pictures were taken using an Axiovert 40CFL microscope
(Olympus, Tokyo, Japan). For quantification of Oil Red
O-based steatosis, HepG2 cells were cultured in a 96-well
microplate at 5000 cells/well with PA plus/minus Oligonol
for 24 h and Oil Red O staining was performed as
described above. After washing and drying completely,
100 μL of extraction solution was added to each well and
the mixtures were incubated for 10 min, followed by
gentle vibration to release Oil Red O. The extraction solu-
tion was then transferred to another 96-well plate for
measurement of optical density (OD) at 500 nm by micro-
plate reader (Versamax; Molecular Devices Corporation,
CA, USA). Tests were performed in triplicates.
Quantitative real-time PCR (qRT-PCR)
One microgram of total RNA purified with RNeasy Mini
Kit (Qiagen, Valencia, CA, USA) was used to synthesize
cDNA (Quanti Tech Reverse Transcription Kit; Qiagen).
cDNA was amplified using SYBR Premix Ex Taq and gene-
specific primers (Table 1) in Takara Thermal Cycler Dice
Real-Time system (Otsu, Shiga, Japan) (95 °C for 5 s, 58 °C
for 10 s, and 72 °C for 20 s for 40 cycles). All reactions were
performed in triplicates and the data were normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Western blot analysis
Proteins were extracted from the cells using extraction
buffer [50 mM Tris HCl, pH 8.0, 5 mM EDTA, 150 mM
NaCl, 0.5 % sodium deoxycholate, 1 % Nonidet P-40,
0.1 % SDS, 1 mM PMSF, 1 mM NaF, 1 mM NaVO4, and
protease inhibitor cocktail (Roche, Germany). Protein
extracts were first separated on 10 % polyacrylamide gels
and electrophoretically transferred onto polyvinylidene
fluoride membrane (Gelman Laboratory, Ann Arbor, MI,
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USA). After blocking, the membranes were incubated
with a primary antibody, and then with horseradish
peroxidase-conjugated IgG (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Blots were developed using ECL
Detection Kit (Amersharm Pharmacia, UK). Primary anti-
bodies to ACC, pACC, HSL, pHSL, FAS, STAT3, pSTAT3,
IRS-1, pIRS-1(Ser363), AMPK, pAMPK, mTOR, pmTOR,
S6K, pS6K were from Cell Signaling Technology (Denver,
MA, USA), PPARγ and pIRS(Tyr632) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), SREBP-1 was
from BD Biosciences (San Jose, CA, USA), and β-actin
was from Sigma (St. Louis, MO, USA). Results of western
blotting were normalized with those obtained for β-
actin. Protein bands were quantified using densitometry
with accompanying software (ImageJ).
Free fatty acids and glycerol assay
After treatment HepG2 cells with a various concentration
of Oligonol in the presence of PA, free fatty acid and free
glycerol contents in the cell supernatants was quantified
using a free fatty acid or glycerol quantification kit
according to the manufacturer’s instructions (Biovision Inc.,
Milpitas, CA, USA). Released free fatty acid or glycerol was
quantified at 570 nm on a 96-well plate reader (Molecular
devices, Mountain View, CA, USA).
Statistical analysis
Data are presented as mean ± SEM. Differences between
the means of each group were analyzed using Student’s
t test or one-way ANOVA test with Dunnett’s multiple
comparison test. P values < 0.05 were considered significant.
The statistical software package Prism 5.0 (GraphPad
Software, La Jolla, CA, USA) was used.
Results
Oligonol attenuated PA-induced intracellular lipid
deposition in HepG2 cells
To assess the cytotoxic effects of Oligonol on HepG2
cells, the cells were treated with various concentrations
of Oligonol (0–50 μg/ml) for 24 and 48 h. Cell viability
did not decrease below 90 % of the control level after
48 h, as determined by the MTT assay, indicating that the
tested concentrations of Oligonol did not grossly affect
cell growth and viability (Fig. 1a). Because the tested con-
centrations did not induce cytotoxicity, 1, 5, or 10 μg/ml
of Oligonol was used for further studies.
Next, we investigated whether Oligonol inhibited
PA-induced intracellular lipid accumulation in HepG2
cells [7]. The cells were incubated in 250 μM PA and
various concentrations of Oligonol for 24 h, and intracel-
lular lipid content was measured using oil red O staining.
PA-treated HepG2 cells showed higher oil red O staining
(Fig. 1b and c) than vehicle-treated control cells, indicating
higher TG content. Oligonol suppressed TG accumulation
in HepG2 cells in a dose-dependent manner.
Oligonol suppressed lipogenesis and enhanced lipolysis
in PA-treated HepG2 cells
Next, we examined the mechanisms underlying the
inhibition of hepatic TG synthesis by Oligonol. Fatty
Table 1 Primer sequences used in this study
Genes Forward primer Reveres primer Tm (C°)
ACC GAAGTCAGAGCCACGGCACA GGCAATCTCAGTTCAAGCCAGTC 62
FAS AGCACTGCCTTCGGTTCAGTC AAGAGCTGTGGAGGCCACTTG 62
SREBP1c CTCCGGCCACAAGGTACACA GAGGCCCTAAGGGTTGACACAG 60
HSL CAAGTGTGTCAGCGCCTATGCT GGGCTTTCTGGTCTGAGTTGGA 64
PPARγ CTTGTGAAGGATGCAAGGGT ATACAAATGCTTTGCCAGGG 62
CPT-1a GGAATGAAATTCCCACTGTCTGTC CAGTTCAGCCATCGCTGTTGTA 60
HADHα ACTTCCAAAGACACCAGTGCTTCA GGCGCAAGACACCTGGTAGTATAGA 60
LCAD CCAGCTGCATGAAGCGAAAC GCTGAACTCTGGCATCCACATAA 60
UCP2 TGTGCCCTTACCATGCTCCA AGGGCTCGTTTCAGCTGCTC 60
CYP2E1 ATGTCTGCCCTCGGAGTGA GATGTCCTTCCAGGTAGGTCC 58
CYP4A11 AGGAGCTCCAACAGGACCAG CCTGATGGGTGAAGGCACAC 68
PPARα TCCTGAGCCATGCAGAATTTAC AGTCTAAGGCCTCGCTGGTG 60
TNFα GACAAGCCTGTAGCCCATGTTGTA CAGCCTTGGCCCTTGAAGA 60
IL-6 GTGGAGATTGTTGCCATCAACG CAGTGGATGCAGGGATGATGTTCTG 60
MCP-1 AGCAGCAAGTGTCCCAAAGA GGTGGTCCATGGAATCCTGA 60
STAT3 GGAATCCCGTGGGTTGCTTAC TTGAATGCAGTGGCCAGGAC 60
SOCS3 CAGGAATGTAGCAGCGATGGAA CCTGTCCAGCCCAATACCTGA 60
GAPDH TGAACGGGAAGCTCACTGG TCCACCACCCTGTTGCTGTA 58–64
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acid synthesis begins with acetyl-CoA and involves the
addition of two carbon units to increase the length of the
fatty acid chain. Acetyl-CoA carboxylase (ACC) converts
acetyl-CoA to malonyl-CoA, which is a rate-limiting step
in lipogenesis [19]. Fatty acid synthase (FAS) utilizes
acetyl-CoA, malonyl-CoA, and NADPH, and elongates
fatty acids chain to form PA [20]. Therefore, we examined
the key enzymes and transcription factors involved in lipid
metabolism in HepG2 cells. Oligonol suppressed the
mRNA and protein expression of ACC, FAS, sterol
regulatory element-binding protein-1 (SREBP-1), and
peroxisome proliferator-activated receptor-γ (PPARγ) in a
dose-dependent manner (Fig. 2a, b, and c), suggesting that
Oligonol suppresses de novo fatty acid synthesis in HepG2
cells. Because Oligonol did not affect the mRNA levels of
hormone sensitive lipase (HSL), we evaluated whether
Oligonol regulated the activity of HSL by analyzing the
levels of phosphorylated HSL in total cell lysates by
performing western blotting. Phosphorylation of HSL
at serine 660 was attenuated in PA-treated HepG2
cells, but all the 3 concentrations of Oligonol increased
HSL phosphorylation. Further, we also found that
phosphorylation of ACC at serine 79 was significantly
increased in Oligonol-treated HepG2 cells (Fig. 2c).
Because Oligonol modulated the expression of genes
involved in hepatic lipid metabolism, we examined whether
the reduction in lipid accumulation was associated with
lipolysis. HepG2 cells were incubated with Oligonol for
24 h, and the amounts of FFAs and glycerol in the culture
medium were measured by performing a colorimetric
assay. Oligonol increased the secretion of glycerol into the
medium in a dose-dependent manner (Fig. 2d). In contrast,
Oligonol did not increase the secretion of FFA into the
medium and significantly decreased the intercellular levels
of FFA (Fig. 2e).
Oligonol increased fatty acid oxidation in PA-treated
HepG2 cells
Next, we examined whether Oligonol enhanced the
degradation of fatty acids through β-oxidation. PA notably
decreased the mRNA level of carnitine palmitoyltransferase
1a (CPT1a) in HepG2 cells, whereas Oligonol increased
the mRNA level of CPT1a in a dose-dependent manner
(Fig. 3a). PA had a similar effect on the level of long-chain
L-3-hydroxyacyl-coenzyme A dehydrogenase α (HADHα).
However, Oligonol had no effect on long-chain acyl-CoA
dehydrogenase (LCAD) under the same condition. We also
found that Oligonol attenuated PA-induced increase in the
mRNA level of uncoupling protein 2 (UCP2), suggesting
that Oligonol has antioxidant properties and protects
hepatocytes from PA-induced lipotoxicity.
ω-Oxidation, an alternative pathway of fatty acid
metabolism, is activated upon failure of β-oxidation.
Previous studies have shown that expression of the cyto-
chrome P450 enzymes CYP2E1 and CYP4A11 is increased
in patients with NAFLD [21] and that PA significantly
A
C
B
Fig. 1 Oligonol attenuated PA-induced increase in intracellular lipid content in HepG2 cells. (a) Oligonol cytotoxicity measurement. HepG2 cells
were incubated with various concentrations of Oligonol (OLG; ranging from 0 to 50 μg/ml) for 24 or 48 h, and cell viability was measured by MTT
assay. (b and c) Cells were treated with 250 μM of palmitate (PA) in the absence or presence of Oligonol (ranging from 1 to 10 μg/ml) for 24 h, and
stained with Oil-red O to visualize the intracellular lipid contents. (b) Lipid contents were quantified by its OD value at 500 nm. Data were presented as
mean ± SEM of three independent experiments; each performed in triplicates. ###P < 0.005 vs. vehicle-treated control; ** P < 0.01, and *** P < 0.005 vs.
palmitate-treated cells (PA). (c) Micrographs of phase contrast microscopy. Control (CTL) is vehicle treated cells. Scale bar is 100 μm
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increases the level of CYP2E1 [22]. Therefore, we exam-
ined whether Oligonol inhibited the expression of these
enzymes. Treatment of HepG2 cells with PA increased the
mRNA levels of CYP2E1 and CYP4A11 by up to three
fold; however, these levels were markedly reduced after
Oligonol treatment.
Transcription factor PPARα directly controls various
steps of hepatic lipid metabolism, including expression of
CPT1a and HADHα [23]. Because these genes are upregu-
lated by Oligonol, we determined whether expression
of PPARα was also upregulated by Oligonol. Oligonol
increased the mRNA level of PPARα in a dose-
A
B
Fig. 3 Oligonol increased lipid oxidation in PA-treated HepG2 cells. HepG2 cells were treated with 250 μM of PA in the absence or presence of
Oligonol (ranging from 1 to 10 μg/ml) for 24 h. (a) CPT1a, HADHα, LCAD, and UCP2 mRNA levels, (b) CYP2E1, CYP4A11, and PPARα mRNA levels
were measured using qRT-PCR. Values were normalized to GAPDH. Data were presented as mean ± SEM of three independent experiments; each
performed in triplicates. White bars represent HepG2 cells treated with vehicle, and black bars represent HepG2 cells treated with PA. #P < 0.05,
##P < 0.01 vs. vehicle-treated control (CTL); *P < 0.05, **P < 0.01, ***P < 0.005 vs. palmitate-treated cells (PA)
(See figure on previous page.)
Fig. 2 Oligonol suppressed lipogenesis while enhancing lipolysis in PA-treated HepG2 cells. HepG2 cells were treated with 250 μM of PA in the
absence or presence of Oligonol (ranging from 1 to 10 μg/ml) for 24 h. (a) ACC, FAS, and SREBP-1c mRNA levels, (b) HSL and PPARγ mRNA levels
were measured by qRT-PCR. Values were normalized to GAPDH and presented as mean ± SEM of three independent experiments; each performed in
triplicates. White bars represent HepG2 cells treated with vehicle, and black bars represent HepG2 cells treated with PA. (c) Protein levels and
phosphorylation states for these five genes were examined by Western blot analysis with appropriate antibodies. β-actin is a loading control. Graphs
represent densitometric analysis of Western blots. (d and e) Released glycerol and FFAs into the culture medium and intracellular FFA contents were
quantified by its OD value at 570 nm. Data were presented as mean ± SEM of three independent experiments; each performed in triplicates. #P < 0.05,
##P < 0.01, ###P < 0.005 vs. vehicle-treated control (CTL); *P < 0.05, **P < 0.01, and ***P < 0.005 vs. palmitate-treated cells (PA)
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dependent manner (Fig. 3b), indicating that Oligonol
improves fatty acid catabolism at the transcriptional level
at least in part by regulating the expression of PPARα.
Oligonol suppressed PA-induced inflammation in
HepG2 cells
Chronic hepatic inflammation is tightly associated with
the pathogenesis of NAFLD [24]. In fact, lipid peroxidation
increases the production of inflammatory cytokines and
mitochondrial dysfunction because β-oxidation generates
increased levels of ROS, leading to oxidative stress [5, 25].
To determine the effect of Oligonol on the mRNA
expression of inflammatory cytokines, HepG2 cells
were treated with Oligonol in the presence of PA. The
mRNA expression of genes encoding inflammatory cyto-
kines tumor necrosis factor α (TNFα), interleukin 6 (IL-6),
and monocytic chemotactic protein 1 (MCP-1) was sig-
nificantly increased after PA treatment. However, Oligonol
treatment at all the three concentrations decreased
the expression of these inflammatory cytokines in a
dose-dependent manner (Fig. 4a). The mRNA expression
of IL-6 in PA-treated cells was ~6-fold higher than that in
untreated cells. We measured the production and secre-
tion of IL-6 by performing enzyme-linked immunosorbent
assay (ELISA) and found that Oligonol decreased the pro-
duction IL-6, which was consistent with the decreased
mRNA levels of IL-6 (Fig. 4b).
Because IL-6 directly activates signal transducer and
activator of transcription 3 (STAT3), the effect of Oligonol
on STAT3 signaling was tested by examining the mRNA
levels of STAT3 and suppressor of cytokine signaling 3
(SOCS3). PA did not increase the mRNA expression of
STAT3. Further, Oligonol suppressed the mRNA expres-
sion of STAT3 by up to ~0.5 fold. PA markedly increased
the mRNA levels of SOCS3 by ~2 fold, which exerts a
negative feedback control in response to the activation of
STAT3 (Fig. 4c). Western blotting analysis of phospho-
STAT3 and STAT3 showed that PA increased the levels of
phospho-STAT3 and that Oligonol decreased the levels
of phospho-STAT3 at all the concentrations tested.
Densitometric analysis showed no statistically significant
decrease in the total level of STAT3. However, STAT3
level was decreased slightly, which was consistent with the
decreased mRNA expression of STAT3 (Fig. 4d).
Oligonol improved PA-induced insulin resistance
Based on our finding that Oligonol suppressed IL-6–
STAT3–SOCS3 signaling in PA-treated HepG2 cells, we
examined the effect of Oligonol on the key proteins
involved in insulin signaling. We examined the changes
in the phosphorylation of insulin receptor substrate-1
(IRS-1) in PA-treated HepG2 cells to assess insulin resist-
ance. IRS-1 activity is either activated or inhibited by the
phosphorylation of specific tyrosine or serine residues [26].
We first confirmed that PA treatment increased IRS-1
phosphorylation at serine 636 (an inhibitory site for insulin
signaling) and decreased IRS-1 phosphorylation at tyrosine
632 (a stimulatory site for insulin signaling). Interestingly,
Oligonol treatment reversed this phosphorylation pattern,
i.e., phosphorylation at serine 636 was attenuated while
that at tyrosine 632 was increased by all the 3 concentra-
tions of Oligonol (Fig. 5a). To further confirm that insulin
resistance was relieved in these cells, we examined
the expression of genes involved in insulin resistance
(INSR, CREB, CRTC, IGFBP-1, and GLUT2). No signifi-
cant differences were observed in the expression of these
genes between cells treated with Oligonol plus PA and
untreated control cells (data not shown).
Oligonol activated AMPK and inhibited mTOR–S6K
pathway in HepG2 cells
AMP-activated protein kinase (AMPK) is a critical
enzyme for regulating hepatic lipogenesis and insulin
resistance. Activated AMPK increases fatty acid oxidation,
lipolysis, and insulin sensitivity in the skeletal muscle, liver,
and adipose tissue [18, 27]. To determine the modulation
of AMPK by Oligonol, AMPK activation was examined by
analyzing its phosphorylation levels in total cell lysates by
Western blot analysis. All the concentrations of Oligonol
equally enhanced the activity of AMPK, as determined
by phosphorylation at threonine 172 compared with that
in untreated control or PA-treated cells. Because AMPK
negatively regulates mammalian target of rapamycin
(mTOR) [28], we investigated whether Oligonol sup-
pressed the activation of mTOR and its downstream
component ribosomal protein S6 kinase (S6K). Western
blotting analysis of mTOR and S6K showed that
Oligonol markedly suppressed the phosphorylation of
both mTOR and S6K in a dose-dependent manner. No
differences were observed in the total protein levels of
AMPK, mTOR, and S6K (Fig. 5b).
Discussion
Many polyphenols exert anti-obesity and hypolipidemic
effects in animals and humans. These compounds have
been investigated as complementary agents because of
their potential beneficial effects on health and biosafety
in various model systems [6, 29]. In the present study,
we observed that Oligonol inhibited de novo fatty acid
synthesis in HepG2 cells. We also found that Oligonol
suppressed the expression of inflammatory cytokines
such as IL-6, thus exhibiting anti-inflammatory effects, and
regulated insulin resistance through the STAT3–SOCS3
and AMPK pathways. In the present study, we used PA,
which is widely used to establish hepatic steatosis models
that show increased FFA production [7]. Fatty acid
metabolism in the liver involves the following steps:
(1) de novo synthesis of fatty acids and uptake of plasma
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FFAs; (2) fatty acid oxidation in the mitochondria,
peroxisomes, and microsomes; (3) neutralization of
ROS generated through fatty acid oxidation; and (4) con-
version of TGs to fatty acids [21]. Oligonol suppressed
both ACC and FAS, which are the primary enzymes
in lipogenesis. Oligonol also suppressed the mRNA
expression of SREBP-1 and PPARγ, indicating that this
anti-lipogenic effect occurred at the transcriptional level.
Lipogenesis is regulated by SREBP-1 and SREBP -2.
Particularly, SREBP-1 positively controls FFA metabolism
by inducing the expression of target genes encoding rate-
limiting enzymes such as ACC and FAS involved in de
A
C
D
B
Fig. 4 Oligonol suppressed inflammation responses induced by PA in HepG2 cells. HepG2 cells were treated with 250 μM of PA in the absence
or presence of Oligonol (ranging from 1 to 10 μg/ml) for 24 h. (a) TNFα, IL-6, and MCP-1 mRNA levels were measured by qRT-PCR. (b) IL-6 released into
the culture medium was assayed. (c) STAT3 and SOCS3 mRNA levels were measured by qRT-PCR. Values were normalized to GAPDH. Data were
presented as mean ± SEM of three independent experiments; each performed in triplicates. White bars represent HepG2 cells treated with
vehicle, and black bars represent HepG2 cells treated with PA. (d) STAT3 activation was examined by its phosphorylation state using Western blot
analysis. β-actin was used as a loading control. Graphs represent densitometric analysis of Western blots. #P < 0.05, ##P < 0.01, ###P < 0.005 vs.
vehicle-treated control (CTL); *P < 0.05, **P < 0.01, and ***P < 0.005 vs. palmitate-treated cells (PA)
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novo lipogenesis [30]. Oligonol activated the enzymes
involved in lipid metabolism. Oligonol increased the phos-
phorylation of ACC and HSL (Fig. 2c). Phosphorylation of
ACC at serine 79, a key phosphorylation site, inactivates
ACC [31]. Thus, phosphorylation of ACC at serine 79 is a
critical step in lipogenesis, indicating that this enzyme is a
potential target for treating dyslipidemia [32]. Oligonol
acts as a regulatory checkpoint in lipid synthesis by
increasing phosphorylation. In fact, the mRNA expression
of ACC, FAS, and SREBP-1 is increased in the livers
of patients with NAFLD [21]. Moreover, liver-specific
ACC1-knockout (LACC1KO) mice show decreased de
novo concentrations of fatty acids and hepatic TGs [33].
Oligonol contributes to lipolysis by simultaneously
inhibiting adipogenesis. Oligonol increases the release of
glycerol from differentiated 3T3-L1adipocytes [34].
Moreover, Oligonol reduces fat content in the adipose
tissues by increasing lipolysis both in vitro and in vivo
[35, 36]. Consistent with previous studies, Oligonol
exerted a lipolytic effect on HepG2 cells in the present
study, suggesting that Oligonol can efficiently regulate
lipid metabolism in the adipose tissues and liver to
prevent dyslipidemia. We further investigated the
effect of Oligonol on the expression of genes associated
with β-oxidation. Oxidation of fatty acids occurs
mainly in the mitochondria. However, excessive fatty
acid production in hepatocytes also activates alterna-
tive pathways such as β-oxidation in the peroxisomes
and ω-oxidation in the microsomes. In patients with
NAFLD, mRNA expression of genes involved in fatty
acid oxidation, such as LCAD, HADHα, CYP2E1, and
CYP4A11, is increased while that of CPT1A and PPARA is
decreased compared with that in the livers of normal
individuals [21, 37]. PA, which is widely used to
establish an in vitro model of fatty liver, mimicked
dyslipidemic conditions by decreasing the mRNA
levels of CPT1a and increasing the mRNA levels of
CYP2E1 and CYP4A11. However, PA did not increase
the mRNA levels of LCAD and HADHα. Moreover,
mRNA levels of HADHα increased after Oligonol
treatment in a dose-dependent manner. Because Oligonol
reduced the mRNA levels of CYP2E1 and CYP4A11,
which were highly induced by PA, it is possible that acute
PA stimulation may disrupt mitochondrial β-oxidation
and alternatively induce ω-oxidation. Thus, Oligonol
reversed PA-induced expression of the above genes,
suggesting that Oligonol facilitates the transport of
long-chain fatty acids into the mitochondria and restores
mitochondrial β-oxidation by increasing the mRNA
expression of CPT1a and HADHα.
Oligonol appears to eliminate excessive amounts of
reactive oxygen species (ROS) produced during lipid
oxidation in the mitochondria. UCP2 is a mitochondrial
inner membrane carrier protein that mediates a proton leak
across the inner membrane and uncouples mitochondrial
electron transport from adenosine triphosphate (ATP)
synthesis [38]. In many pathophysiological conditions
such as NAFLD and obesity, UCP2 levels are elevated,
indicating increased oxidative stress [6, 39]. Our results
showed that PA-induced UCP2 levels were inhibited by
Oligonol, suggesting that Oligonol functions as an antioxi-
dant and decreases the levels of ROS in HepG2 cells.
However, this result was not consistent with the observa-
tion that Oligonol increased the gene expression of CPT1A
and HADHα and enhanced β-oxidation because increased
β-oxidation induces ROS production. Therefore, it is
conceivable that UCP2 levels may increase upon Oligonol
treatment. However, UCP2 is not normally expressed in
hepatocytes [40]; thus, the role of UCP2 in hepatocytes
should be elucidated in further studies. Transcription of
UCP2 is regulated by other conditions such as energy
expenditure and inflammation.
On the other hand, increase in the levels of inflammatory
cytokines is associated with UCP2 expression. Incubation
of hepatocytes with FFA increases the production of ROS
and mRNA level of UCP2 [41], leading to oxidative stress.
Overproduction of ROS also activates nuclear factor kappa
beta (NF-kB) [42], a major transcription factor, that upre-
gulates the expression of various cytokine such as TNFα
and IL-6 and contributes to mitochondrial dysfunction and
increased ROS production. In fact, serum and hepatic
levels of TNFα, IL-1, and IL-6 were elevated in a mouse
model of NAFLD and patients with NAFLD [43–45].
Conversely, anti-cytokine antibodies decreased inflam-
mation and prevented dyslipidemia and NAFLD in a
mouse model [46, 47]. Thus, it is possible that PA induces
acute inflammation and expression of TNFα and IL-6 in
HepG2 cells. The above data indicate that these cytokines
and not β-oxidation increase ROS production, leading to
the upregulation of UCP2 mRNA levels. Thus, Oligonol
may act as an antioxidant or anti-inflammatory agent to
reduce the levels of UCP2.
Many studies have shown that hepatic steatosis is tightly
associated with insulin resistance and obesity. A previous
(See figure on previous page.)
Fig. 5 Oligonol attenuated PA-induced insulin resistance in HepG2 cells with concomitant activation of AMPK and suppression of the mTOR
pathway. HepG2 cells were treated with 250 μM of PA in the absence or presence of Oligonol (ranging from 1 to 10 μg/ml) for 24 h. The
phosphorylation states of (a) IRS-1 or (b) AMPK, mTOR, and S6K were examined by Western blot analysis with appropriate antibodies. β-actin
was used as a loading control. Graphs represent densitometric analysis of Western blots. #P < 0.05, ##P < 0.01, ###P < 0.005 vs. vehicle-treated
control (CTL); *P < 0.05, **P < 0.01, and ***P < 0.005 vs. palmitate-treated cells (PA)
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study reported that 40–100 % obese people have comor-
bidities such as NAFLD and that 21–55 % obese people
have type 2 diabetes or hyperglycemia [48]. Increased
levels of inflammatory cytokines play an important in the
development of insulin resistance. TNFα was the first
cytokine to be identified that impaired insulin action [49].
In obese rodent models and humans with NAFLD or
obesity, a strong inverse correlation has been observed
between serum TNFα levels and insulin-stimulated
glucose metabolism [50, 51]. Although mechanisms
involved in TNFα-induced insulin resistance are not
completely understood, compelling evidence indicates that
TNFα inhibits IRS-1- and IRS-2-mediated PI3-kinase
activation, leading to insulin resistance [52]. IL-6 is
another important cytokine involved in the regulation of
insulin resistance. IL-6 promotes insulin resistance by
activating the STAT3–SOCS3 pathway in the liver [53].
Activation of STAT3 by phosphorylation subsequently
increases SOCS3 expression through a negative feedback
mechanism. SOCS3 then directly disrupts insulin signal-
ing through ubiquitin-mediated degradation of IRS
[18, 54]. In the present study, Oligonol modulated recipro-
cal phosphorylation of IRS-1 by increasing the phosphor-
ylation of the stimulatory residue tyrosine 632 and by
decreasing the phosphorylation of the inhibitory residue
serine 636, thus restoring insulin signaling. We further
examined the expression levels of genes involved in insu-
lin resistance. However, no changes were observed in the
expression of these genes. To further understand the
effects of Oligonol, a study involving a high-fat-induced
obese mouse model should be performed to determine
the comprehensive role of Oligonol in lipid metabolism.
In our previous study, Oligonol inhibited TG accumula-
tion and lipogenesis by suppressing Akt–mTOR pathway in
3T3-L1 adipocytes [34]. Therefore, we tested whether
Oligonol had the same anti-lipogenic effect on hepatic stea-
tosis by using PA-treated HepG2 cells. Activated AMPK
inhibits ATP-consuming processes such as synthesis of fatty
acids or sterols and activates ATP-producing processes
such as fatty acid oxidation [55]. Once activated through
phosphorylation at threonine 172 residue in its α subunit,
AMPK inhibits hepatic lipogenesis by phosphorylating
ACC at the inhibitory serine 79 residue and by downregu-
lating SREBP-1c [55]. Because Oligonol suppresses lipo-
genic gene expression and ACC activation (Fig. 2), we
hypothesized that Oligonol activates AMPK and conse-
quently inhibits lipogenic processes. As expected, Oligonol
potently activated AMPK at all the tested concentrations
and subsequently inhibited mTOR activation, thus inhibit-
ing IRS-1 [26]. Interestingly, an anti-diabetic agent metfor-
min, which activates AMPK in hepatocytes, exerted
beneficial effects on lipid metabolism by suppressing
the activity of ACC and reducing the expression of
lipogenic enzymes [56]. Thus, the AMPK–mTOR pathway
is a potential therapeutic target for treating hepatic steato-
sis. Oligonol showed a similar mechanism of action, indi-
cating its beneficial effects in preventing insulin resistance
and hepatic steatosis. IL-6 plays a paradoxical role in insu-
lin signaling, which improves insulin sensitivity after phys-
ical exercise. Ruderman et al. reported that IL-6 treatment
of both muscle cells and adipocytes increased AMPK and
ACC phosphorylation. Similar findings were observed in
the muscle of mice after exercise. Moreover, these effects
were decreased in IL-6 knockout mice [57]. IL-6 treat-
ment improved insulin-induced glucose disposal and was
accompanied by increased glucose transporter-4 (GLUT4)
translocation to the plasma membrane and activation of
AMPK [58]. However, IL-6-induced AMPK activation
appears to be an acute response in skeletal muscle tissues
after exercise. Low-grade chronic elevation of IL-6 is the
primary cause of NAFLD. Thus, the prolonged effect of
IL-6 on AMPK needs to be investigated further in hepatic
steatosis models.
Conclusions
NAFLD is one of the most common causes of liver dys-
function. Excessive FFAs in the liver induce oxidative stress,
inflammatory cytokine production, mitochondrial dysfunc-
tion, and insulin resistance, which all contribute to
disease progression. In this study, we provided evidence that
Oligonol has a protective effect on PA-induced cellular stea-
tosis in HepG2 cells. Oligonol suppressed lipogenesis, while
promoting fatty acid oxidation and lipolysis. PA-induced
IL-6 production and STAT3 phosphorylation were signifi-
cantly repressed by Oligonol. In addition, Oligonol inhibited
mTOR phosphorylation by AMPK activation. Our results
demonstrated that Oligonol may prevent hepatic steatosis
by regulating AMPK-mTOR and STAT3-SOCS3 signaling
pathways, and that these pathways are good therapeutic
targets for treating hepatic dysfunction.
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